Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

A new effort led by a University of California, Irvine Medical Center oncologist seeks to improve cancer survival for adolescents and young adults. Dr. Leonard S. Sender has long advocated changing the approach oncologists take when treating patients and survivors aged 15 to 39.

7 May 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Researchers discover new mechanism by which BRCA1 gene mutations can induce breast cancer

Two researchers from the Centre for Genomic Regulation in Barcelona have discovered a new mechanism by which mutations in gene BRCA1 can induce breast cancer.

5 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

Centocor Ortho Biotech Products withdraws NDA for trabectedin for treatment of women with ROC

Centocor Ortho Biotech Products, L.P., today announced that it has voluntarily withdrawn the New Drug Application for trabectedin for the treatment of women with recurrent ovarian cancer. The withdrawal is based on the U.S. Food and Drug Administration's recommendation that an additional Phase 3 study be conducted to obtain approval.

30 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

GPs could offer simple test for early detection of ovarian cancer

Health experts have said that hundreds of lives could be saved a year if GPs were quicker to spot symptoms of the disease - dubbed a “silent killer” because it is hard to diagnose early enough. Ovarian cancer kills almost 4,400 women in Britain every year. It kills one every two hours that makes it the fourth most common cancer in females. While almost three times as many die from breast cancer, those diagnosed with ovarian cancer are far more likely to die earlier.

28 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Motor regulatory protein can block human ovarian tumor growth

A motor regulatory protein can block human ovarian tumor growth, leading to eventual cancer cell death and possible new therapies to treat the disease, according to Penn State College of Medicine researchers.

27 Apr 2011

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.

26 Apr 2011

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

More than 1,800 Chinese oncology professionals attended the NCCN 4th Annual Asia Scientific Congress in Shanghai, China, on April 9, 2011, which featured expert faculty from NCCN Member Institutions and thought leaders in cancer care from major Chinese cancer centers.

25 Apr 2011

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

NYU Langone Medical Center announced today the U.S. Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs has awarded Silvia Formenti, MD, the Sandra and Edward Meyer Professor and Chair of the Department of Radiation Oncology a $4.5 million Multi-Team Award to conduct novel breast cancer research.

21 Apr 2011

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.

20 Apr 2011

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

20 Apr 2011

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.

19 Apr 2011

Study finds more evidence linking high-grade serous ovarian cancer to fallopian tubes

High-grade serous ovarian cancer (HGSOC), the fifth-deadliest cancer among American women, is thought by many scientists to often be a fallopian tube malignancy masquerading as an ovarian one. While most of the evidence linking HGSOC to the fallopian tubes has so far been only circumstantial, a new Dana-Farber Cancer Institute study suggests there is a direct connection, a finding that could aid in the development of better treatments for the cancer.

19 Apr 2011

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

16 Apr 2011

Major pharmaceutical company, Access sign deal for RNAi therapeutics

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

15 Apr 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

CytRx reports $6.3 million net loss for first quarter 2011

Researchers discover new mechanism by which BRCA1 gene mutations can induce breast cancer

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Centocor Ortho Biotech Products withdraws NDA for trabectedin for treatment of women with ROC

Celgene non-GAAP total revenue increases 40% to $1.11 billion

GPs could offer simple test for early detection of ovarian cancer

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

Motor regulatory protein can block human ovarian tumor growth

Colorectal cancer patients with genetic mutation can benefit from new class of drugs

Oncologists discuss about NCCN updated guidelines at 4th Annual Asia Scientific Congress

U.S. DOD awards $4.5M to NYU Langone Medical Center for novel breast cancer research

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

OSU biophysicist leverages computer cluster to develop drug to block small protein molecule IL-6

Ohio State biophysicist disrupts cellular messages through fragment-based drug design

Study finds more evidence linking high-grade serous ovarian cancer to fallopian tubes

NVP-BEZ235 inhibits growth of ovarian cancer cells, increases survival: Study

Major pharmaceutical company, Access sign deal for RNAi therapeutics

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in